Convergence Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Convergence Investment Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,682	Closed	-$1.87M	–	254
2026 Q1	$1.87M	Buy	75,682 +39,092	+107%	+$931K	0.31%	115
2025 Q4	$854K	Buy	36,590 +364	+1%	+$8.11K	0.17%	183
2025 Q3	$714K	Sell	36,226 -18,680	-34%	-$384K	0.16%	179
2025 Q2	$1.19M	Buy	+54,906	New	+$1.3M	0.3%	124
2023 Q1	–	Sell	-7,935	Closed	-$148K	–	195
2022 Q4	$148K	Buy	+7,935	New	+$122K	0.09%	184

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Convergence Investment Partners's CPRX Position: Q2 2026 in Review

Convergence Investment Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 75,682 shares — an estimated $1.87M sold.

Convergence Investment Partners first reported a position in CPRX in Q4 2022 and held it in 5 quarters. The position peaked at $1.87M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Convergence Investment Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Convergence Investment Partners sold 75,682 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.87M.
Convergence Investment Partners first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 5 quarters.
Convergence Investment Partners's Catalyst Pharmaceutical position peaked at $1.87M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.